STUDY FOR PREVENTION OF BREAST CANCER

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。一项大型临床试验的证据表明，他莫昔芬有助于降低罹患乳腺癌风险增加的女性的乳腺癌发病率。美国食品和药物管理局(FDA)已批准他莫昔芬用于此类用途。雷洛昔芬已被FDA和加拿大卫生保护局(HPB)批准用于预防绝经后妇女的骨质疏松症(骨质疏松)。研究人员认为，雷洛昔芬也可能降低患乳腺癌的风险，而且副作用比他莫昔芬更少。FDA和HPB认为使用雷洛昔芬降低乳腺癌风险目前还处于实验阶段。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Evidence from a large clinical trial shows that tamoxifen helps to reduce the incidence of breast cancer in women who are at increased risk for developing the disease. The U.S. Food and Drug Administration (FDA) has approved tamoxifen for such use. Raloxifene has been approved by the FDA and the Canadian Health Protection Branch (HPB) for the prevention of osteoporosis (thinning of bones) in postmenopausal women. Researchers think raloxifene may also reduce the risk of developing breast cancer and have fewer side effects than tamoxifen. The FDA and the HPB consider the use of raloxifene for reducing the risk of breast cancer to be experimental at this time.